Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 716

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis

Open access
Busse, Jason W., Wang, Li, Kamaleldin, Mostafa, Craigie, Samantha, Riva, John J., Montoya, Luis, Mulla, Sohail M., Lopes, Luciane C., Vogel, Nicole, Chen, Eric, Kirmayr, Karin, De Oliveira, Kyle, Olivieri, Lori, Kaushal, Alka, Chaparro, Luis E., Oyberman, Inna, Agarwal, Arnav, Couban, Rachel, Tsoi, Ludwig, Lam, Tommy, Vandvik, Per Olav, Hsu, Sandy, Bala, Malgorzata M., Schandelmaier, Stefan, Scheidecker, Anne, Ebrahim, Shanil, Ashoorion, Vahid, Rehman, Yasir, Hong, Patrick J., Ross, Stephanie, Johnston, Bradley C., Kunz, Regina, Sun, Xin, Buckley, Norman, Sessler, Daniel I., Guyatt, Gordon H.·2018·JAMA
DOI 10.1001/jama.2018.18472
Open this paper in CoChat — free account

Abstract

Importance: Harms and benefits of opioids for chronic noncancer pain remain unclear. Objective: To systematically review randomized clinical trials (RCTs) of opioids for chronic noncancer pain. Data Sources and Study Selection: The databases of CENTRAL, CINAHL, EMBASE, MEDLINE, AMED, and PsycINFO were searched from inception to April 2018 for RCTs of opioids for chronic noncancer pain vs any nonopioid control. Data Extraction and Synthesis: Paired reviewers independently extracted data. The analyses used random-effects models and the Grading of Recommendations Assessment, Development and Evaluation to rate the quality of the evidence. Main Outcomes and Measures: The primary outcomes were pain intensity (score range, 0-10 cm on a visual analog scale for pain; lower is better and the minimally important difference [MID] is 1 cm), physical functioning (score range, 0-100 points on the 36-item Short Form physical component score [SF-36 PCS]; higher is better and the MID is 5 points), and incidence of vomiting. Results: Ninety-six RCTs including 26 169 participants (61% female; median age, 58 years [interquartile range, 51-61 years]) were included. Of the included studies, there were 25 trials of neuropathic pain, 32 trials of nociceptive pain, 33 trials of central sensitization (pain present in the absence of tissue damage), and 6 trials of mixed types of pain. Compared with placebo, opioid use was associated with reduced pain (weighted mean difference [WMD], -0.69 cm [95% CI, -0.82 to -0.56 cm] on a 10-cm visual analog scale for pain; modeled risk difference for achieving the MID, 11.9% [95% CI, 9.7% to 14.1%]), improved physical functioning (WMD, 2.04 points [95% CI, 1.41 to 2.68 points] on the 100-point SF-36 PCS; modeled risk difference for achieving the MID, 8.5% [95% CI, 5.9% to 11.2%]), and increased vomiting (5.9% with opioids vs 2.3% with placebo for trials that excluded patients with adverse events during a run-in period). Low- to moderate-quality evidence suggested similar associations of opioids with improvements in pain and physical functioning compared with nonsteroidal anti-inflammatory drugs (pain: WMD, -0.60 cm [95% CI, -1.54 to 0.34 cm]; physical functioning: WMD, -0.90 points [95% CI, -2.69 to 0.89 points]), tricyclic antidepressants (pain: WMD, -0.13 cm [95% CI, -0.99 to 0.74 cm]; physical functioning: WMD, -5.31 points [95% CI, -13.77 to 3.14 points]), and anticonvulsants (pain: WMD, -0.90 cm [95% CI, -1.65 to -0.14 cm]; physical functioning: WMD, 0.45 points [95% CI, -5.77 to 6.66 points]). Conclusions and Relevance: In this meta-analysis of RCTs of patients with chronic noncancer pain, evidence from high-quality studies showed that opioid use was associated with statistically significant but small improvements in pain and physical functioning, and increased risk of vomiting compared with placebo. Comparisons of opioids with nonopioid alternatives suggested that the benefit for pain and functioning may be similar, although the evidence was from studies of only low to moderate quality.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2018.18472

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 91

  1. Van Zee, 2009, The promotion and marketing of oxycontin: commercial triumph, public health tragedy., Am J Public Health, 99, 221, 10.2105/AJPH.2007.131714 · DOI · Paper page
  2. Volkow, 2016, Opioid abuse in chronic pain., N Engl J Med, 374, 1253, 10.1056/NEJMra1507771 · DOI · Paper page
  3. Vowles, 2015, Rates of opioid misuse, abuse, and addiction in chronic pain., Pain, 156, 569, 10.1097/01.j.pain.0000460357.01998.f1 · DOI · Paper page
  4. Furlan, 2011, A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain., Pain Res Manag, 16, 337, 10.1155/2011/465281 · DOI
  5. Busse, 2015, Optimal strategies for reporting pain in clinical trials and systematic reviews., J Rheumatol, 42, 1962, 10.3899/jrheum.141440 · DOI
  6. Busse, 2013, Opioids for chronic non-cancer pain., Syst Rev, 2, 66, 10.1186/2046-4053-2-66 · DOI
  7. Turk, 2008, Identifying important outcome domains for chronic pain clinical trials., Pain, 137, 276, 10.1016/j.pain.2007.09.002 · DOI · Paper page
  8. Goshua, Patient values and preferences regarding opioids for chronic noncancer pain: a systematic review, Pain Med
  9. Nielsen, 2016, A synthesis of oral morphine equivalents (OME) for opioid utilisation studies., Pharmacoepidemiol Drug Saf, 25, 733, 10.1002/pds.3945 · DOI · Paper page
  10. Tendal, 2011, Multiplicity of data in trial reports and the reliability of meta-analyses: empirical study., BMJ, 343, d4829, 10.1136/bmj.d4829 · DOI
  11. Thorlund, 2011, Pooling health-related quality of life outcomes in meta-analysis—a tutorial and review of methods for enhancing interpretability., Res Synth Methods, 2, 188, 10.1002/jrsm.v2.3 · doi:10.1002/jrsm.v2.3
  12. Schünemann, 2005, Commentary—goodbye M(C)ID! hello MID, where do you come from?, Health Serv Res, 40, 593, 10.1111/hesr.2005.40.issue-2 · doi:10.1111/hesr.2005.40.issue-2
  13. Ward, 2014, Clinically important changes in Short Form 36 health survey scales for use in rheumatoid arthritis clinical trials., Arthritis Care Res (Hoboken), 66, 1783, 10.1002/acr.v66.12 · doi:10.1002/acr.v66.12
  14. Caldwell, 1999, Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs., J Rheumatol, 26, 862
  15. Cloutier, 2013, Controlled-release oxycodone and naloxone in the treatment of chronic low back pain: a placebo-controlled, randomized study, Pain Res Manag, 18, 75, 10.1155/2013/164609 · DOI
  16. Hale, 2015, Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back pain., J Opioid Manag, 11, 507, 10.5055/jom.2015.0304 · DOI
  17. Jamison, 1998, Opioid therapy for chronic noncancer back pain: a randomized prospective study., Spine (Phila Pa 1976), 23, 2591, 10.1097/00007632-199812010-00014 · DOI · Paper page
  18. Khoromi, 2007, Morphine, nortriptyline and their combination vs placebo in patients with chronic lumbar root pain., Pain, 130, 66, 10.1016/j.pain.2006.10.029 · DOI · Paper page
  19. Webster, 2006, Oxytrex minimizes physical dependence while providing effective analgesia., J Pain, 7, 937, 10.1016/j.jpain.2006.05.005 · DOI
  20. Gimbel, 2016, Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain, Pain, 157, 2517, 10.1097/j.pain.0000000000000670 · DOI
  21. Afilalo, 2010, Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee., Clin Drug Investig, 30, 489, 10.2165/11533440-000000000-00000 · DOI · Paper page
  22. Arai, 2015, Two placebo-controlled, randomized withdrawal studies to evaluate the fentanyl 1 day patch in opioid-naïve patients with chronic pain., Curr Med Res Opin, 31, 2207, 10.1185/03007995.2015.1092127 · DOI
  23. Babul, 2004, Efficacy and safety of extended-release, once-daily tramadol in chronic pain., J Pain Symptom Manage, 28, 59, 10.1016/j.jpainsymman.2003.11.006 · DOI · Paper page
  24. Bennett, 2003, Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain., Am J Med, 114, 537, 10.1016/S0002-9343(03)00116-5 · DOI · Paper page
  25. Breivik, 2010, A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naïve to potent opioids., Scand J Pain, 1, 122, 10.1016/j.sjpain.2010.05.035 · DOI
  26. Burch, 2007, A comparison of the analgesic efficacy of tramadol contramid OAD versus placebo in patients with pain due to osteoarthritis., J Pain Symptom Manage, 34, 328, 10.1016/j.jpainsymman.2006.11.017 · DOI
  27. Buynak, 2010, Efficacy and safety of tapentadol extended release for the management of chronic low back pain., Expert Opin Pharmacother, 11, 1787, 10.1517/14656566.2010.497720 · DOI · Paper page
  28. Christoph, 2017, Cebranopadol, a novel first-in-class analgesic drug candidate., Pain, 158, 1813, 10.1097/j.pain.0000000000000986 · DOI
  29. DeLemos, 2011, Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip., Am J Ther, 18, 216, 10.1097/MJT.0b013e3181cec307 · DOI
  30. Emkey, 2004, Efficacy and safety of tramadol/acetaminophen tablets (ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug., J Rheumatol, 31, 150
  31. Fishman, 2007, Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once-daily tramadol (tramadol contramid OAD)., J Opioid Manag, 3, 273, 10.5055/jom.2007.0015 · DOI
  32. Fleischmann, 2001, Tramadol for the treatment of joint pain associated with osteoarthritis., Curr Ther Res Clin Exp, 62, 113, 10.1016/S0011-393X(01)80021-7 · DOI
  33. Friedmann, 2011, Efficacy and safety of an extended-release oxycodone (remoxy) formulation in patients with moderate to severe osteoarthritic pain., J Opioid Manag, 7, 193, 10.5055/jom · DOI
  34. Gana, 2006, Extended-release tramadol in the treatment of osteoarthritis., Curr Med Res Opin, 22, 1391, 10.1185/030079906X115595 · DOI
  35. Hale, 2010, Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain., Curr Med Res Opin, 26, 1505, 10.1185/03007995.2010.484723 · DOI
  36. Hale, 2007, Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients., J Pain, 8, 175, 10.1016/j.jpain.2006.09.011 · DOI · Paper page
  37. Hanna, 2008, Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients., Eur J Pain, 12, 804, 10.1016/j.ejpain.2007.12.010 · DOI · Paper page
  38. Katz, 2010, Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain., Postgrad Med, 122, 112, 10.3810/pgm.2010.07.2179 · DOI
  39. Katz, 2015, A phase 3, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of Xtampza ER in patients with moderate-to-severe chronic low back pain., Pain, 156, 2458, 10.1097/j.pain.0000000000000315 · DOI
  40. Katz, 2007, A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain., Curr Med Res Opin, 23, 117, 10.1185/030079906X162692 · DOI
  41. Mayorga, 2016, Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis., Int J Clin Pract, 70, 493, 10.1111/ijcp.2016.70.issue-6 · doi:10.1111/ijcp.2016.70.issue-6
  42. Peloso, 2004, Analgesic efficacy and safety of tramadol/acetaminophen combination tablets (ultracet) in treatment of chronic low back pain., J Rheumatol, 31, 2454
  43. Rauck, 2013, Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS® hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis., Pain Pract, 13, 18, 10.1111/papr.2012.13.issue-1 · doi:10.1111/papr.2012.13.issue-1
  44. Rauck, 2015, A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain treatment., Pain, 156, 1660, 10.1097/j.pain.0000000000000230 · doi:10.1097/j.pain.0000000000000230
  45. Rauck, 2014, Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain., Pain Med, 15, 975, 10.1111/pme.12377 · DOI
  46. Rauck, 2016, Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain., Postgrad Med, 128, 1, 10.1080/00325481.2016.1128307 · DOI
  47. Ruoff, 2003, Tramadol/acetaminophen combination tablets for the treatment of chronic lower back pain., Clin Ther, 25, 1123, 10.1016/S0149-2918(03)80071-1 · DOI · Paper page
  48. Schwartz, 2011, Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy., Curr Med Res Opin, 27, 151, 10.1185/03007995.2010.537589 · DOI · Paper page
  49. Serrie, 2017, Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain., Curr Med Res Opin, 33, 1423, 10.1080/03007995.2017.1335189 · DOI
  50. Simpson, 2016, Transdermal buprenorphine relieves neuropathic pain., Diabetes Care, 39, 1493, 10.2337/dc16-0123 · DOI
  51. Steiner, 2011, Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain., J Pain Symptom Manage, 42, 903, 10.1016/j.jpainsymman.2011.04.006 · DOI
  52. Tominaga, 2016, Methodological issues in conducting pilot trials in chronic pain as randomized, double-blind, placebo-controlled studies., Drug Res (Stuttg), 66, 363, 10.1055/s-00023610 · DOI
  53. Trenkwalder, 2015, Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson’s disease (PANDA)., Lancet Neurol, 14, 1161, 10.1016/S1474-4422(15)00243-4 · DOI
  54. Vinik, 2014, A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy., Diabetes Care, 37, 2302, 10.2337/dc13-2291 · DOI
  55. Vojtaššák, 2011, A phase IIIb, multicentre, randomised, parallel-group, placebo-controlled, double-blind study to investigate the efficacy and safety of OROS hydromorphone in subjects with moderate-to-severe chronic pain induced by osteoarthritis of the hip or the knee., Pain Res Treat, 2011, 239501
  56. Vorsanger, 2008, Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain., J Opioid Manag, 4, 87, 10.5055/jom.2008.0013 · DOI
  57. Weil, 2017, Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain., Health Qual Life Outcomes, 15, 202, 10.1186/s12955-017-0749-y · DOI
  58. Wen, 2015, A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain., Expert Opin Pharmacother, 16, 1593, 10.1517/14656566.2015.1060221 · DOI
  59. Caldwell, 2002, Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain., J Pain Symptom Manage, 23, 278, 10.1016/S0885-3924(02)00383-4 · DOI · Paper page
  60. Chu, 2012, Analgesic tolerance without demonstrable opioid-induced hyperalgesia., Pain, 153, 1583, 10.1016/j.pain.2012.02.028 · DOI
  61. Freeman, 2007, Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy., Curr Med Res Opin, 23, 147, 10.1185/030079906X162674 · DOI
  62. Gilron, 2005, Morphine, gabapentin, or their combination for neuropathic pain., N Engl J Med, 352, 1324, 10.1056/NEJMoa042580 · DOI · Paper page
  63. Gilron, 2015, Combination of morphine with nortriptyline for neuropathic pain., Pain, 156, 1440, 10.1097/j.pain.0000000000000149 · DOI
  64. Gimbel, 2003, Controlled-release oxycodone for pain in diabetic neuropathy., Neurology, 60, 927, 10.1212/01.WNL.0000057720.36503.2C · DOI · Paper page
  65. Gordon, 2010, Buprenorphine transdermal system in adults with chronic low back pain., Clin Ther, 32, 844, 10.1016/j.clinthera.2010.04.018 · DOI
  66. Gordon, 2010, Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain., Pain Res Manag, 15, 169, 10.1155/2010/216725 · DOI
  67. Harati, 1998, Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy., Neurology, 50, 1842, 10.1212/WNL.50.6.1842 · DOI · Paper page
  68. Langford, 2006, Transdermal fentanyl for improvement of pain and functioning in osteoarthritis., Arthritis Rheum, 54, 1829, 10.1002/(ISSN)1529-0131 · DOI · Paper page
  69. Lee, 2013, A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of the extended-release tramadol hydrochloride/acetaminophen fixed-dose combination tablet for the treatment of chronic low back pain., Clin Ther, 35, 1830, 10.1016/j.clinthera.2013.09.017 · DOI
  70. Ma, 2008, The efficacy of oxycodone for management of acute pain episodes in chronic neck pain patients., Int J Clin Pract, 62, 241, 10.1111/ijcp.2008.62.issue-2 · doi:10.1111/ijcp.2008.62.issue-2
  71. Matsumoto, 2005, Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis., Pain Med, 6, 357, 10.1111/j.1526-4637.2005.00057.x · DOI
  72. Moran, 1991, MST continus tablets and pain control in severe rheumatoid arthritis., Br J Clin Res, 2, 1
  73. Peloso, 2000, Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee., J Rheumatol, 27, 764
  74. Thorne, 2008, A randomized, double-blind, crossover comparison of the efficacy and safety of oral controlled-release tramadol and placebo in patients with painful osteoarthritis., Pain Res Manag, 13, 93, 10.1155/2008/165421 · DOI
  75. Uberall, 2012, Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain., Curr Med Res Opin, 28, 1617, 10.1185/03007995.2012.726216 · DOI
  76. Zin, 2010, A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin., J Pain, 11, 462, 10.1016/j.jpain.2009.09.003 · DOI
  77. Chen, 2014, Clinical interpretation of opioid tolerance versus opioid-induced hyperalgesia., J Opioid Manag, 10, 383, 10.5055/jom.2014.0235 · DOI
  78. Salsitz, 2016, Chronic pain, chronic opioid addiction: a complex nexus., J Med Toxicol, 12, 54, 10.1007/s13181-015-0521-9 · DOI
  79. Ballantyne, 2015, Opioid therapy in chronic pain., Phys Med Rehabil Clin N Am, 26, 201, 10.1016/j.pmr.2014.12.001 · DOI
  80. Juurlink, 2017, Rethinking “doing well” on chronic opioid therapy., CMAJ, 189, E1222, 10.1503/cmaj.170628 · DOI
  81. Macfarlane, 2017, EULAR revised recommendations for the management of fibromyalgia., Ann Rheum Dis, 76, 318, 10.1136/annrheumdis-2016-209724 · DOI · Paper page
  82. Ballantyne, 2016, Avoiding opioid analgesics for treatment of chronic low back pain., JAMA, 315, 2459, 10.1001/jama.2016.6753 · DOI
  83. Abdel Shaheed, 2016, Efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain., JAMA Intern Med, 176, 958, 10.1001/jamainternmed.2016.1251 · DOI · Paper page
  84. Naliboff, 2011, A randomized trial of 2 prescription strategies for opioid treatment of chronic nonmalignant pain., J Pain, 12, 288, 10.1016/j.jpain.2010.09.003 · DOI
  85. Gomes, 2014, Trends in high-dose opioid prescribing in Canada., Can Fam Physician, 60, 826
  86. Fernandes, 2016, High-dose opioid prescribing and opioid-related hospitalization., PLoS One, 11, e0167479, 10.1371/journal.pone.0168658 · DOI
  87. Edlund, 2010, Trends in use of opioids for chronic noncancer pain among individuals with mental health and substance use disorders., Clin J Pain, 26, 1, 10.1097/AJP.0b013e3181b99f35 · DOI · Paper page
  88. Davis, 2017, Prescription opioid use among adults with mental health disorders in the United States., J Am Board Fam Med, 30, 407, 10.3122/jabfm.2017.04.170112 · DOI · Paper page
  89. Murad, 2015, Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 507
  90. Gelman, 2007, Data Analysis Using Regression and Multilevel/Hierarchical Models, 529
  91. International Narcotics Control Board. Narcotic drugs: estimated world requirements for 2018: statistics for 2016. https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2017/Narcotic_drugs_technical_publication_2017.pdf. Accessed October 25, 2018. · doi:10.18356/55c75c37-en-fr-es

Cited by

See all 716

Metadata

Authors
Busse, J. W., Wang, L., Kamaleldin, M., Craigie, S., Riva, J. J., Montoya, L., Mulla, S. M., Lopes, L. C., Vogel, N., Chen, E., Kirmayr, K., De Oliveira, K., Olivieri, L., Kaushal, A., Chaparro, L. E., Oyberman, I., Agarwal, A., Couban, R., Tsoi, L., Lam, T., Vandvik, P. O., Hsu, S., Bala, M. M., Schandelmaier, S., Scheidecker, A., Ebrahim, S., Ashoorion, V., Rehman, Y., Hong, P. J., Ross, S., Johnston, B. C., Kunz, R., Sun, X., Buckley, N., Sessler, D. I., & Guyatt, G. H.
Venue
JAMA
Publisher
American Medical Association (AMA)
Published
2018-12-18
Volume
320
Issue
23
Pages
2448
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
DOI
10.1001/jama.2018.18472
OpenAlex
W2904363872
Cited by
716
References
20
FWCI
62.55
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis. https://app.cochat.ai/papers/10.1001/jama.2018.18472
The paper
Busse, J. W., Wang, L., Kamaleldin, M., Craigie, S., Riva, J. J., Montoya, L., Mulla, S. M., Lopes, L. C., Vogel, N., Chen, E., Kirmayr, K., De Oliveira, K., Olivieri, L., Kaushal, A., Chaparro, L. E., Oyberman, I., Agarwal, A., Couban, R., Tsoi, L., . . . Guyatt, G. H. (2018). Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis. JAMA. https://doi.org/10.1001/jama.2018.18472

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.